Vaishali Pharma Limited has informed the Exchange regarding Board meeting held on February 13, 2026.
VAISHALI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vaishali Pharma's board approved unaudited Q3 FY26 (Dec 2025) standalone and consolidated results along with a preferential share-swap deal to acquire a stake in Kesar Pharma Limited. Revenue from operations for Q3 FY26 stood at Rs. 2,465.19 lakhs, down about 12% from Rs. 2,791.43 lakhs in Q3 FY25. For 9M FY26, revenue fell to Rs. 6,677.98 lakhs from Rs. 9,902.56 lakhs in 9M FY25, a sharp decline of roughly 33%. Profit after tax for 9M FY26 was Rs. 376.52 lakhs vs Rs. 510.99 lakhs in 9M FY25. The board approved issuing up to 61.23 lakh equity shares at Rs. 20 each (face value Rs. 2, premium Rs. 18), aggregating Rs. 12.25 crores, entirely through a share swap to acquire 21.52 lakh equity shares (~20.33%) of Kesar Pharma. The statutory auditor issued an unmodified limited review report on both standalone and consolidated results.
The sharp year-on-year revenue decline is a concern, though Q3 PAT improved sequentially from Q2. The share-swap acquisition will result in roughly 4.48% dilution for existing shareholders, but no cash outflow is involved. Subject to shareholder and regulatory approvals.